Literature DB >> 21606964

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

J Piñón Hofbauer1, C Heyder, U Denk, T Kocher, C Holler, D Trapin, D Asslaber, I Tinhofer, R Greil, A Egle.   

Abstract

Chronic lymphocytic leukemia (CLL) cells require complex microenvironmental and immunologic interactions to survive and proliferate. Such interactions might be best recreated in animal models; however, this needs extensive verification. We therefore investigated the composition of the T-cell compartment in the Eμ-TCL1 transgenic mouse, currently the most widely used murine model for CLL. Immunophenotyping and transplant approaches were used to define T-cell subsets at various stages of CLL. Analogous to human CLL, we observed a skewing of T-cell subsets from naive to antigen-experienced memory T cells that was more pronounced in lymph nodes than in blood. Transplantation of CLL into non-transgenic recipients was feasible without immunosuppression in a pure C57BL/6 background and resulted in the prominent skewing of the T cells of the recipient mice. Both in spontaneously developed CLL and in the transplantation setting, a loss in T-cell receptor diversity was observed, with a relevant number of clonal T-cell populations arising. This suggests that antigen-dependent differentiation toward the T memory pool is initiated by murine CLL cells. In summary, we validate the TCL1 transgenic mouse model for analysis of T-cell phenotypes and suggest a CLL-dependent antigen-driven skewing of T cells in these mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606964     DOI: 10.1038/leu.2011.111

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  47 in total

1.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

2.  B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.

Authors:  Daniela Asslaber; Yuan Qi; Nicole Maeding; Markus Steiner; Ursula Denk; Jan Philip Höpner; Tanja Nicole Hartmann; Nadja Zaborsky; Richard Greil; Alexander Egle
Journal:  Blood       Date:  2019-11-14       Impact factor: 22.113

3.  CD84 mediates CLL-microenvironment interactions.

Authors:  A Marom; A F Barak; M P Kramer; H Lewinsky; I Binsky-Ehrenreich; S Cohen; A Tsitsou-Kampeli; V Kalchenko; Y Kuznetsov; V Mirkin; N Dezorella; M Shapiro; P L Schwartzberg; Y Cohen; L Shvidel; M Haran; S Becker-Herman; Y Herishanu; I Shachar
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

Review 4.  Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

Authors:  Kamira Maharaj; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Blood Adv       Date:  2017-09-26

5.  BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.

Authors:  Yo-Ting Tsai; Aparna Lakshmanan; Amy Lehman; Bonnie K Harrington; Fabienne McClanahan Lucas; Minh Tran; Ellen J Sass; Meixiao Long; Alan D Flechtner; Florinda Jaynes; Krista La Perle; Vincenzo Coppola; Gerard Lozanski; Natarajan Muthusamy; John C Byrd; Michael R Grever; David M Lucas
Journal:  Blood Adv       Date:  2017-10-30

Review 6.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 7.  The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Authors:  Yuri Pekarsky; Alessandra Drusco; Prasanthi Kumchala; Carlo M Croce; Nicola Zanesi
Journal:  Gene Expr       Date:  2015

Review 8.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

9.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

10.  Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.

Authors:  Vincent K Nganga; Victoria L Palmer; Hina Naushad; Michele D Kassmeier; Dirk K Anderson; Greg A Perry; Nathan M Schabla; Patrick C Swanson
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.